HHV-6 is the causative agent of exanthema subitum in children. The main modes of transmission of HHV-6 are body secretions such as infected saliva but it can be transmitted with blood and blood products that are infected with the virus. Therefore, it is thought that the immunocompromised hemodialysis patients who had multiple blood transfusions due to various reasons, and who collectively use devices such as hemodialysis machines are at risk for HHV-6 infection. The present study aimed to determine the incidence of HHV-6 infection in hemodialysis patients. Twenty-five healthy individuals that were matched with 25 hemodialysis patients in terms of gender and age were included in the study. The IgM and IgG sero-prevalence in the patient and control groups were investigated with the indirect fluorescence antibody method and HHV-6 DNA prevalence and the determination of variant types (variant A and variant B) were investigated with the PCR-RFLP molecular method. HHV-6 IgG and HHV-6 IgM antibody positivity ratios in the patient and control groups were 76% and 20% respectively. Out of 50 serum samples of hemodialysis patients and healthy individuals, HHV-6 DNA was positive in seven of 25 samples of hemodialysis patients (28%) and it was positive in eight of 25 samples of the control group (32%). Variant analysis was performed with the PCR-RFLP method in HHV-6 DNA positive hemodialysis patients and control patients. At the end of the analysis, while variant A was not detected in the patient and control groups, variant B was detected in a total of 15 individuals, including seven patients in the hemodialysis patient group and eight patients in the control group. In conclusion, the researchers believe that there is a need for controlled studies including more samples to determine the clinical importance of HHV-6 DNA and HHV-6 variants in hemodialysis patients.